Q
QuantAbundanciaAbundance, Quantified.

News

High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.

24,540 signal articles · 208 in last 24h · 116,908 total before filter · latest 20m ago
208last 24h
1683last 7d
274● bullish (7d)
150● bearish (7d)
205publishers
AllMacro317Earnings751M&A99Regulatory25Product15Analyst25
✕ clear all filterssentiment: bullishSentiment:bullishneutralbearish✓ showing all (incl. clickbait)
Did Datadog’s (DDOG) AI-Fueled Q1 2026 Surge Just Shift Its Investment Narrative?
Simply Wall St.39d agobullish
Did Datadog’s (DDOG) AI-Fueled Q1 2026 Surge Just Shift Its Investment Narrative?

In recent days, Datadog reported past first-quarter 2026 results with revenue reaching over US$1.00 billion, accelerating growth, record new logo bookings, and a flurry of AI-focused product launches and an acquisition to deepen its observability and AI agent capabilities. At the same time, opinions on Datadog diverged sharply, with some investors highlighting AI-driven momentum and rising earnings estimates while others questioned sustainability beyond AI workloads amid tougher upcoming...

PepsiCo Revenue Tops Forecasts as Global Volumes Strengthen (PEP)
InvestorsHub39d agobullish
PepsiCo Revenue Tops Forecasts as Global Volumes Strengthen (PEP)

PepsiCo Delivers Revenue Beat in Second QuarterPepsiCo (NASDAQ:PEP) reported second-quarter results that exceeded revenue expectations, although adjusted earnings per share came in just below Wall Street forecasts. Investors reacted positively, sending the stock around 1% higher following the announcement.

Investing.com39d agobullish
Memory monthly sales hit record $74.6B as analysts see price surge ahead

Investing.com - Global memory monthly sales reached a record $74.6 billion, surging 31.7% month-on-month and running 2.8 percentage points above the 10-year seasonal average, according to UBS's July Memory Monthly report — a data point that has both UBS and Bernstein forecasting sharp contract price increases ahead, even as the two firms diverge sharply on how long the rally can last.

PepsiCo’s (NASDAQ:PEP) Q2 CY2026 Sales Beat Estimates
StockStory39d agobullish
PepsiCo’s (NASDAQ:PEP) Q2 CY2026 Sales Beat Estimates

Food and beverage company PepsiCo (NASDAQ:PEP) reported Q2 CY2026 results exceeding the market’s revenue expectations, with sales up 6.4% year on year to $24.18 billion. Its non-GAAP profit of $2.20 per share was 1.2% below analysts’ consensus estimates.

Lyft CEO on surge pricing, robotaxis, and Bezos
Yahoo Finance Video39d agobullishVIDEO
Lyft CEO on surge pricing, robotaxis, and Bezos

Lyft CEO David Risher unpacks his playbook with Yahoo Finance Executive Editor Brian Sozzi for turning the rideshare giant around, from ending traditional surge pricing and mandating a return-to-office, to building a hybrid future of human drivers and Waymo robotaxis.

HIVE Digital (HIVE): The Best Crypto Penny Stock to Buy Now
Insider Monkey39d agobullish
HIVE Digital (HIVE): The Best Crypto Penny Stock to Buy Now

HIVE Digital Technologies Ltd. (NASDAQ:HIVE) is one of the 8 Best Crypto Penny Stocks to Buy Now. On June 25, 2026, HIVE Digital Technologies Ltd. (NASDAQ:HIVE) announced that it signed a non-binding letter of intent with an investment-grade, sovereign Swedish technology company for an up to 10-year lease of HIVE’s 32 megawatt Boden, Sweden facility. […]

3 Market-Beating Stocks for Long-Term Investors
StockStory39d agobullish
3 Market-Beating Stocks for Long-Term Investors

Companies that consistently increase their sales, margins, or returns on capital are usually rewarded with the best returns, and those that can do all three for years on end are almost always the legendary stocks that return 100 times your money.

Gilead Sciences (GILD) Wins Trodelvy Approvals And Expands Texas CAR T Access
Simply Wall St.39d agobullish
Gilead Sciences (GILD) Wins Trodelvy Approvals And Expands Texas CAR T Access

Gilead Sciences (NasdaqGS:GILD) received FDA approval for Trodelvy in first line treatment of advanced triple negative breast cancer. European regulators also approved Trodelvy in the same setting for eligible patients. The company entered a partnership with BBG Advanced Therapies to deploy a mobile center offering Kite CAR T cell therapies across Texas. These updates place oncology and cell therapy firmly at the center of Gilead Sciences' story, alongside its established presence in...